ValiRx PLC Marketing and Communications Update
July 10 2019 - 2:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
10 July 2019
VALIRX PLC
("ValiRx" or the "Company")
MARKETING AND COMMUNICATIONS UPDATE
London, UK., 10 July 2019: ValiRx Plc (AIM: VAL), the AIM-quoted
clinical stage biotechnology company is pleased to announce a
marketing and communications update for shareholders.
Dr Satu Vainikka, Chief Executive, will be delivering a
presentation to investors at the SVS Securities and UK Investor
Magazine investor evening on Thursday 18 July 2019 at the Skinners
Hall, 8 1/2 Dowgate Hill, London EC4R 2SP, which commences at
6:00pm (for registration) until 11:00pm.
Those wishing to register for this complimentary event may do so
through the following link:
https://www.eventbrite.co.uk/e/uk-investor-magazine-svs-securities-summer-investor-evening-tickets-62427386995
A copy of the presentation will be available to investors on the
evening and will be available to view on the Company's website
shortly after the event.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Novum Securities Limited Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABXGDRLBGBGCC
(END) Dow Jones Newswires
July 10, 2019 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024